Mr. Philippe Dubuc reports

THERATECHNOLOGIES ANNOUNCES ALL U.S. ONCOLOGY CLINICAL SITES NOW ENROLLING FOR PHASE 1 TRIAL OF SUDOCETAXEL ZENDUSORTIDE

All five of the United States-based clinical sites participating in the conduct of the phase 1 clinical trial of Theratechnologies Inc.'s lead investigational peptide drug conjugate, sudocetaxel zendusortide, are now activated to screen, enroll and dose advanced ovarian cancer patients. A sixth site based in Canada is finalizing its start-up activity.

Full details about the study design, participation criteria and contact information for the sites can be found at the Clinical Trails government website.

About sudocetaxel zendusortide and SORT1+ Technology

Sudocetaxel zendusortide is currently Theratechnologies' lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology. It is the company's proprietary peptide linked to docetaxel -- a commonly used cytotoxic agent used to treat many cancers. The FDA (United States Food and Drug Administration) granted fast track designation to sudocetaxel zendusortide as a single agent for the treatment of all sortilin-positive recurrent advanced solid tumours that are refractory to standard therapy. Sudocetaxel zendusortide is currently being evaluated in a phase 1 clinical trial.

Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology for cancer drug development targeting SORT1 receptors. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. It is highly expressed in cancer cells compared with healthy tissue, which makes SORT1 an attractive target for cancer drug development. Expression of SORT1 is associated with aggressive disease, poor prognosis and decreased survival. It is estimated that the SORT1 receptor is expressed in 40 per cent to 90 per cent of cases of endometrial, ovarian, colorectal, triple-negative breast and pancreatic cancers.

About Theratechnologies Inc.

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.

We seek Safe Harbor.